Role of PRKDC in cancer initiation, progression, and treatment

Cancer Cell International

Xuefeng Wang¹  Xiaobin Zheng²  Chuanben Chen²  Yu Chen³  Bin Lan³  Jun Liu³  Jing Lin³  Jiani Xiong³  Yi Li⁴  Zhaodong Fei⁴ 

[1] CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences;Cancer Bio-Immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital;Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital;Department of Radiation Oncology, Fujian Medical University Cancer Hospital & Fujian Cancer Hospital;

关键词: PRKDC;    DNA-dependent protein kinase catalytic subunit;    Tumorigenesis;    Cancer progression;    Cancer treatment;   

DOI  :  10.1186/s12935-021-02229-8

来源: DOAJ

【 摘 要 】

Abstract The PRKDC gene encodes the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) protein. DNA-PKcs plays an important role in nonhomologous end joining (NHEJ) of DNA double-strand breaks (DSBs) and is also closely related to the establishment of central immune tolerance and the maintenance of chromosome stability. The occurrence and development of different types of tumors and the results of their treatment are also influenced by DNA-PKcs, and it may also predict the results of radiotherapy, chemotherapy, and therapy with immune checkpoint inhibitors (ICIs). Here, we discuss and review the structure and mechanism of action of PRKDC and DNA-PKcs and their relationship with cancer.

【 授权许可】

Unknown